Veru, EyePoint Pharmaceuticals, SINTX Technologies Among Healthcare Movers

Seeking AlphaApr 18 22:00

Daily Futures Tracking | The bearish ratio has been rising for two days in a row! Tesla's two-card push doubles and soars

AMD's bullish ratio rose to 63% for two consecutive days. Calls due on Friday and with an exercise price of $165/170 were active, at 68,000 and 41,000, respectively.

Futu NewsApr 17 16:55

Strong Buy Rating for EyePoint Pharmaceuticals Amid Promising Developments in Ophthalmic Therapies

Tim Chiang, an analyst from Capital One Financial, maintained the Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report). The associated price target remains the same with $50.00.

TipRanksApr 13 02:15

Recent EyePoint Weakness Seen As Buying Opportunity -- Market Talk

0756 ET - A recent sell-off in shares of EyePoint Pharmaceuticals is an opportunity to buy, according to Mizuho. In a research note, analyst Graig Suvannavejh says a more than 30% drop in EyePoint sha

WSJApr 3 19:57

Revenue Downgrade: Here's What Analysts Forecast For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Market forces rained on the parade of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shareholders today, when the analysts downgraded their forecasts for this year.

Simply Wall StMar 10 21:48

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%

Yahoo FinanceMar 9 21:32